Olivier Brandicourt appointed as new CEO of Bayer HealthCare
- Details
- Category: Bayer
Olivier Brandicourt (57) has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer AG Executive Council effective November 1, 2013. Since March 2013, Professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer AG Board Member.
Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy
- Details
- Category: Boehringer Ingelheim
New analysis of data from the LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor that targets three receptors crucially involved in angiogenesis and tumour growth, provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.(1)
Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
- Details
- Category: UCB
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). PsA is a chronic, inflammatory condition that causes pain, swelling and stiffness in and around the joints and tendons, and usually occurs in combination with psoriasis.(1,2)
Bayer's investigational drug Riociguat granted FDA orphan drug designation
- Details
- Category: Bayer
Bayer HealthCare today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted two separate orphan drug designations for its investigational, oral medication riociguat for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
Amgen and ShanghaiTech University announce plans for Amgen China R&D center
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and ShanghaiTech University today announced the two organizations have entered into a memorandum of understanding (MOU) to form a strategic partnership for the advancement of biopharmaceutical discovery and translational research in China. This agreement includes plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University.
Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths
- Details
- Category: Novartis
Novartis and Malaria No More announced today the debut of the Power of One campaign, encouraging people around the world to help end child deaths from malaria. Novartis will support the campaign financially and donate up to three million Coartem® Dispersible treatments to match antimalarials funded by the public.
GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) plc has announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services (HHS), for the provision of its inhalation anthrax treatment, raxibacumab. The US government is purchasing the medicine as a counter measure against a potential bioterrorist attack.
More Pharma News ...
- Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
- Bayer fights Chagas disease in Argentina together with Caritas
- Christoph Franz nominated to become new Roche Chairman
- AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
- Novartis announces an exclusive global licensing and research collaboration with Regenerex
- Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
- Onglyza® (saxagliptin) achieves primary safety endpoint in SAVOR cardiovascular outcomes trial